build on or conduct dredge and fill operations in United States waters. Opinions on the quality of service are used to make program improvements.

Affected Public: Business or Other for Profit.

Annual Burden Hours: 15,000. Number of Respondents: 60,000. Responses per Respondent: 1. Average Burden per Response: 15 inutes.

Frequency: On occasion.

SUPPLEMENTARY INFORMATION: The Corps will conduct surveys of customers at our districts, division and headquarters offices, currently a total of 49 offices. Most customer responses will be solicited by the 38 districts. These elements will tabulate their survey results and send copies to headquarters for a Corps wide tabulation. The survey form will be provided to the public when they receive a regulatory product, primarily a permit decision or wetland determination.

Luz Ortiz,

Army Federal Register Liaison Officer. [FR Doc. 02–5908 Filed 3–11–02; 8:45 am] BILLING CODE 3710–08–M

DEPARTMENT OF DEFENSE

Department of the Army

Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning High-Throughput Assays for the Proteolytic Activities of Clostridial Neurotoxins

AGENCY: Department of the Army, DoD. **ACTION:** Notice.

SUMMARY: In accordance with 37 CFR 404.6, announcement is made of the availability for licensing of U.S. Patent Application No. 09/962,260 entitled "High Throughput Assays for the Proteolytic Activities of Clostridial Neurotoxins" filed September 25, 2001. Foreign rights are also available (PCT/US01/30188). The United States Government as represented by the Secretary of the Army has rights in this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR–JA, 504 Scott Street, Fort Detrick, Frederick, Maryland 21702–5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619–7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment,

(301) 619–6664, both at telefax (301) 619–5034.

SUPPLEMENTARY INFORMATION: In this application are described substrates for high-throughput assays of clostridial neurotoxin proteolytic activities. Two types of substrates are described for use in assays for the proteolytic activities of clostridial neurotoxins: (1) Modified peptides or proteins that can serve as FRET substrates and (2) modified peptides or proteins that can serve as immobilized substrates. In both types a fluorescent molecules is present in the substrate, eliminating the requirement for the addition of a fluorigenic reagent. The assays described can be readily adapted for use in automated or robotic systems.

Luz D. Ortiz,

Army Federal Register Liaison Officer. [FR Doc. 02–5903 Filed 1–11–02; 8:45 am] BILLING CODE 3710–08–M

DEPARTMENT OF DEFENSE

Department of the Army

Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning Compositions and Methods for Reducing Blood and Fluid Loss From Open Wounds

AGENCY: Department of the Army, DoD. **ACTION:** Notice.

SUMMARY: In accordance with 37 CFR 404.6, announcement is made of the availability for licensing of U.S. Patent Application No. 60/300,384 entitled "Compositions and Methods for Reducing Blood and Fluid Loss from Open Wounds" filed June 22, 2001. The United States Government as represented by the Secretary of the Army has rights in this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR–JA, 504 Scott Street, Fort Detrick, Frederick, Maryland 21702–5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619–7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619–6664, both at telefax (301) 619–5034.

SUPPLEMENTARY INFORMATION: The invention described herein relates to methods for reducing and/or stopping bleeding or fluid loss from open wound, denuded tissue or burned skin, comprising the step of applying to the

open wound, denuded tissue or burned skin a gel-forming composition comprising at least one of the following compositions: a polyacrylic acid having the structural formula [ČH₂=CHCO₂H]n, where n is between 10.000 and 70.000: a polyacrylic acid and a dessicated water soluble organic or inorganic base; polyacrylic acid and a dessicated poorly soluble basic salt, and a polyvinyl alcohol having the structural formula of [CH₂=CHOH]n, where n is between 15,000 and 150,000. When the gelforming composition is applied to the open wound, denuded tissue, or burned skin, its ions react therein the presence of water from blood or body fluid therein to form an aqueous gel or mucilage having sufficient viscosity and adhesiveness to cover and adhere to the open wound, denuded tissue, or burned skin so that bleeding or fluid loss is thereby reduced and/or stopped.

Luz D. Ortiz,

Army Federal Register Liaison Officer. [FR Doc. 02–5902 Filed 3–11–02; 8:45 am] BILLING CODE 3710–08–M

DEPARTMENT OF DEFENSE

Department of the Army

Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning Method for Detecting Clostridium Botulinum Neurotoxin Serotypes A, B, E and F in a Sample

AGENCY: Department of the Army, DoD. **ACTION:** Notice.

SUMMARY: In accordance with 37 CFR 404.6, announcement is made of the availability for licensing of U.S. Patent Application No. 09/952,078 entitled "Method for Detecting Clostridium Botulinum Neurotoxin Serotypes A, B, E and F in a Sample" filed September 14, 2001. Foreign rights are also available (PCT/US01/28641). The United States Government as represented by the Secretary of the Army has rights in this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR–JA, 504 Scott Street, Fort Detrick, Frederick, Maryland 21702–5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619–7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619–6664, both at telefax (301) 619–5034.